AAAAAA

   
Results: 1-7 |
Results: 7
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer
Authors: Rivera, E Valero, V Syrewicz, L Rahman, Z Esteva, FL Theriault, RL Rosales, MM Booser, D Murray, JL Bast, RC Hortobagyi, GN
Citation: E. Rivera et al., Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer, J CL ONCOL, 19(6), 2001, pp. 1716-1722
Canalicular stenosis secondary to docetaxel (Taxotere) - A newly recognized side effect
Authors: Esmaeli, B Valero, V Ahmadi, MA Booser, D
Citation: B. Esmaeli et al., Canalicular stenosis secondary to docetaxel (Taxotere) - A newly recognized side effect, OPHTHALMOL, 108(5), 2001, pp. 994-995
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma
Authors: Cristofanilli, M Buzdar, AU Sneige, N Smith, T Wasaff, B Ibrahim, N Booser, D Rivera, E Murray, JL Valero, V Ueno, N Singletary, ES Hunt, K Strom, E McNeese, M Stelling, C Hortobagyi, GN
Citation: M. Cristofanilli et al., Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, CANCER, 92(7), 2001, pp. 1775-1782
Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer
Authors: Munster, PN Buzdar, A Dhingra, K Enas, N Ni, L Major, M Melemed, A Seidman, A Booser, D Theriault, R Norton, L Hudis, C
Citation: Pn. Munster et al., Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer, J CL ONCOL, 19(7), 2000, pp. 2002-2009
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
Authors: Rivera, E Holmes, FA Frye, D Valero, V Theriault, RL Booser, D Walters, R Buzdar, AU Dhingra, K Fraschini, G Hortobagyi, GN
Citation: E. Rivera et al., Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy, CANCER, 89(11), 2000, pp. 2195-2201
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy
Authors: Hoff, PM Valero, V Buzdar, AU Singletary, SE Theriault, RL Booser, D Asmar, L Frye, D McNeese, MD Hortobagyi, GN
Citation: Pm. Hoff et al., Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy, CANCER, 88(9), 2000, pp. 2054-2060
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer
Authors: Valero, V Buzdar, AU Theriault, RL Azarnia, N Fonseca, GA Willey, J Ewer, M Walters, RS Mackay, B Podoloff, D Booser, D Lee, LW Hortobagyi, GN
Citation: V. Valero et al., Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer, J CL ONCOL, 17(5), 1999, pp. 1425-1434
Risultati: 1-7 |